tiprankstipranks
Advertisement
Advertisement
Revolution Medicines price target raised to $240 from $235 at Guggenheim
PremiumThe FlyRevolution Medicines price target raised to $240 from $235 at Guggenheim
12h ago
Marc Frahm Reiterates Buy on Revolution Medicines, Citing Strong Daraxonrasib Uptake and Best-in-Class KRAS Pipeline Momentum
Premium
Ratings
Marc Frahm Reiterates Buy on Revolution Medicines, Citing Strong Daraxonrasib Uptake and Best-in-Class KRAS Pipeline Momentum
12h ago
Revolution Medicines Earns Buy as Strong RAS Portfolio Data, Robust Launch Prep, and $5.4B Capital Base Drive Price Target Increase to $291
Premium
Ratings
Revolution Medicines Earns Buy as Strong RAS Portfolio Data, Robust Launch Prep, and $5.4B Capital Base Drive Price Target Increase to $291
21h ago
Tango Therapeutics price target raised to $40 from $36 at Mizuho
PremiumThe FlyTango Therapeutics price target raised to $40 from $36 at Mizuho
20d ago
Revolution Medicines price target raised to $235 from $205 at Guggenheim
Premium
The Fly
Revolution Medicines price target raised to $235 from $205 at Guggenheim
28d ago
RASolute 305: RVMD Targets KRAS G12D Pancreatic Cancer in a Pivotal Phase 3 Trial
Premium
Company Announcements
RASolute 305: RVMD Targets KRAS G12D Pancreatic Cancer in a Pivotal Phase 3 Trial
29d ago
Revolution Medicines price target raised to $235 from $183 at Needham
PremiumThe FlyRevolution Medicines price target raised to $235 from $183 at Needham
1M ago
Revolution Medicines begins treating patients in RASolute 305 trial
Premium
The Fly
Revolution Medicines begins treating patients in RASolute 305 trial
1M ago
Revolution Medicines Announces R&D Leadership Transition and Governance Votes
Premium
Company Announcements
Revolution Medicines Announces R&D Leadership Transition and Governance Votes
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100